Viridian Therapeutics (STU:1S1) Selling and Marketing Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Viridian Therapeutics's Selling and Marketing Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Viridian Therapeutics Selling and Marketing Expense Historical Data

The historical data trend for Viridian Therapeutics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Selling and Marketing Expense Chart

Viridian Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Selling and Marketing Expense

Get a 7-Day Free Trial

Viridian Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Selling and Marketing Expense	Get a 7-Day Free Trial															-	-	-	-	-

Viridian Therapeutics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Viridian Therapeutics Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

VRDN:USA 0K1R:UK

Address

221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines